LCM
KYMR icon

Laurion Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Laurion Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,987
Closed -$3.11M – 626
2021
Q4 		$3.11M Hold
48,987
– – 0.03% 232
2021
Q3 		$2.88M Buy
+48,987
New +$2.84M 0.01% 403

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Laurion Capital Management's KYMR Position: Q1 2022 in Review

Laurion Capital Management sold out of Kymera Therapeutics (KYMR) in Q1 2022, closing a stake of 48,987 shares — an estimated $3.11M sold.

Laurion Capital Management first reported a position in KYMR in Q3 2021 and held it in 2 quarters. The position peaked at $3.11M in Q4 2021. 126 funds tracked by Wall St. Rank hold KYMR as of Q1 2022.

  • Laurion Capital Management reported no remaining Kymera Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Laurion Capital Management sold 48,987 Kymera Therapeutics shares in Q1 2022, an estimated $3.11M.
  • Laurion Capital Management first reported a position in Kymera Therapeutics in Q3 2021 and held it in 2 quarters.
  • Laurion Capital Management's Kymera Therapeutics position peaked at $3.11M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2022.

Based on Laurion Capital Management's 13F filing for Q1 2022, filed 16 May 2022.